Roberto N Miranda Selected Research

Genetic Predisposition to Disease (Genetic Predisposition)

1/2019	Differences in Human Leukocyte Antigen Expression Between Breast Implant-Associated Anaplastic Large Cell Lymphoma Patients and the General Population.
2/2017	Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roberto N Miranda Research Topics

Disease

46	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2022 - 04/2012
37	Neoplasms (Cancer) 10/2022 - 10/2004
28	Lymphoma (Lymphomas) 06/2022 - 08/2011
19	T-Cell Lymphoma (Lymphoma, T Cell) 01/2022 - 07/2012
12	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2017 - 01/2011
8	Disease Progression 01/2022 - 01/2013
7	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2018 - 03/2010
4	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 09/2022 - 06/2013
4	B-Cell Lymphoma (Lymphoma, B Cell) 12/2021 - 11/2012
4	Blast Crisis (Blast Phase) 01/2020 - 03/2011
4	Seroma 01/2020 - 01/2017
3	Fibrosis (Cirrhosis) 10/2021 - 10/2003
3	Eosinophilia 01/2021 - 09/2015
3	Inflammation (Inflammations) 01/2020 - 05/2005
3	Chromosome Aberrations (Chromosome Abnormalities) 12/2017 - 04/2010
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2017 - 03/2011
3	Large Granular Lymphocytic Leukemia 01/2017 - 10/2015
3	Infections 12/2016 - 12/2006
2	Hypoxia (Hypoxemia) 01/2021 - 10/2017
2	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 01/2019
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 09/2020 - 05/2016
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 08/2011
2	Genetic Predisposition to Disease (Genetic Predisposition) 01/2019 - 02/2017
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2019 - 08/2011
2	Mycosis Fungoides 01/2018 - 01/2016
2	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 02/2016
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2016 - 03/2011
2	Thrombocytopenia (Thrombopenia) 11/2015 - 12/2002
2	Lymphadenopathy 10/2015 - 03/2012
2	Genetic Translocation (Chromosomal Translocation) 12/2014 - 04/2010
2	Epstein-Barr Virus Infections 08/2014 - 08/2013
1	Sinus Histiocytosis (Rosai-Dorfman Disease) 01/2022
1	Foreign Bodies (Foreign Body) 10/2021
1	Contracture 05/2021
1	Residual Neoplasm 01/2021
1	Rare Diseases (Rare Disease) 06/2020
1	Primary Effusion Lymphoma 04/2020
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2020
1	Burns 01/2020
1	Pdgfra-Associated Chronic Eosinophilic Leukemia 11/2018
1	Spontaneous Remission 01/2018
1	Hypersensitivity (Allergy) 01/2018

Drug/Important Bio-Agent (IBA)

10	Capsules (Microcapsules)IBA 12/2021 - 07/2012
8	Anaplastic Lymphoma KinaseIBA 06/2022 - 09/2009
7	Biological ProductsIBA 01/2020 - 03/2015
6	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2018 - 07/2012
6	Rituximab (Mabthera)FDA Link 12/2015 - 01/2011
5	AntigensIBA 01/2022 - 06/2013
4	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 01/2021 - 09/2015
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2013
4	CytokinesIBA 01/2020 - 12/2016
4	Tyrosine Kinase InhibitorsIBA 01/2020 - 12/2012
3	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2021
3	Cyclin D1IBA 01/2022 - 04/2002
3	Phosphotransferases (Kinase)IBA 01/2021 - 10/2012
3	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 12/2012
3	Vincristine (Oncovin)FDA LinkGeneric 11/2015 - 01/2011
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2015 - 01/2011
2	SiliconesIBA 10/2021 - 12/2020
2	RNA (Ribonucleic Acid)IBA 01/2021 - 11/2012
2	Immunoglobulin M (IgM)IBA 09/2020 - 05/2016
2	Phenobarbital (Luminal)FDA Link 01/2020 - 01/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2020 - 01/2015
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2020 - 12/2012
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2020 - 08/2016
2	ibrutinibIBA 01/2020 - 02/2016
2	Interleukin-13IBA 01/2020 - 01/2018
2	Bortezomib (Velcade)FDA Link 10/2017 - 02/2016
2	Granzymes (Granzyme)IBA 02/2017 - 11/2012
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2017 - 08/2013
2	Azathioprine (Imuran)FDA LinkGeneric 02/2017 - 08/2013
2	Methotrexate (Mexate)FDA LinkGeneric 11/2015 - 08/2013
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 09/2015 - 04/2010
2	Tyrosine (L-Tyrosine)FDA Link 12/2014 - 10/2012
2	Thalidomide (Thalomid)FDA Link 12/2014 - 08/2013
2	Prednisone (Sone)FDA LinkGeneric 11/2012 - 01/2011
2	Serine (L-Serine)FDA Link 10/2012 - 08/2011
1	AsbestosIBA 10/2022
1	Mitogen-Activated Protein KinasesIBA 01/2022
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2022
1	Immune Checkpoint ProteinsIBA 01/2021
1	Interleukin-9 (Interleukin 9)IBA 01/2020
1	Interleukin-10 (Interleukin 10)IBA 01/2020
1	Interleukin-22 (IL-22)IBA 01/2020
1	ChemokinesIBA 01/2020
1	LigandsIBA 01/2020
1	InterferonsIBA 01/2020
1	Chimeric Antigen ReceptorsIBA 01/2020
1	HLA-A Antigens (HLA-A)IBA 01/2019
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2019
1	Immunoglobulin E (IgE)IBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 10/2017

Therapy/Procedure

44	Breast Implants (Breast Implant) 10/2022 - 09/2009
24	Therapeutics 12/2021 - 12/2002
9	Drug Therapy (Chemotherapy) 12/2016 - 03/2012
3	Splenectomy 01/2017 - 11/2012
1	Immunotherapy 01/2020
1	Organ Transplantation 01/2020
1	Mammaplasty (Breast Reconstruction) 01/2019
1	Induction Chemotherapy 12/2017